Karyopharm Therapeutics Inc. (25K0)
Market Closed
17 Jul, 20:00
XDUS 
€
8. 20
+0.05
+0.6135%
€
- Market Cap
- P/E Ratio
- Div Yield
0 Volume
-1.17 Eps
€ 8.15
Previous Close Want to track 25K0 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Karyopharm Therapeutics Inc. (25K0) Statistics
Valuation metrics
Market Cap -
Enterprise value 173.07M
Trailing P/E (ttm) -
Forward P/E -
PEG ratio -
Price/Sales (ttm) -
Price/Book (mrq) -0.36
Enterprise Value/Revenue 1.18
Enterprise Value/EBITDA -1.98
Overview
Shares outstanding 18.31M
Float -
Shares short -
% Held by insiders -
% Held by institutions -
Average volume (10 days) 10
Average volume (90 days) 3
Price summary
52-Week low 3.16
52-Week high 9.2
Beta -
50-Day moving average 6.66
200-Day moving average 5.86
Dividends and splits
Forward annual dividend rate -
Forward annual dividend yield -
Trailing annual dividend rate -
Trailing annual dividend yield -
5-Year annual dividend yield -
Payout ratio -
Dividend Date -
Ex-Dividend Date -
Last split factor 1:15
Last split Date 26 Feb 2025
Financials
Fiscal year
Fiscal year ends 31 Dec 2025
Most recent quarter (mrq) 31 Dec 2025
Profitability
Profit margin 0.96%
Operating margin -1.03%
Operational effectiveness
Return on assets -1.81%
Return on equity 0.67%
Income Statement
Revenue (ttm) 146.07M
Revenue per share (ttm) -
Quarterly revenue growth (yoy) -0.23%
Gross profit (ttm) 140.12M
EBITDA -
Net income to common (ttm) -196.04M
Diluted EPS (ttm) -
Quarterly earnings growth (yoy) 0.32%
Balance Sheet
Total cash (mrq) -
Total cash per share (mrq) -
Total debt (mrq) 233.61M
Total Debt/Equity (mrq) -0.8
Current ratio (mrq) 1.12%
Book value per share (mrq) -16.36
Cash Flow
Cash flow statement -159.81M
Levered free cash flow (LFCF) -196.04M
